Literature DB >> 26051430

Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease.

Salman H Siddiqui1, Alessandro Guasconi2, Jørgen Vestbo3, Paul Jones4, Alvar Agusti5,6, Pierluigi Paggiaro7, Jadwiga A Wedzicha8, Dave Singh9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26051430      PMCID： PMC4595668          DOI： 10.1164/rccm.201502-0235LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  7 in total

1.  Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations.

Authors:  J A Wedzicha; D Singh; J Vestbo; P L Paggiaro; P W Jones; F Bonnet-Gonod; G Cohuet; M Corradi; S Vezzoli; S Petruzzelli; A Agusti
Journal:  Respir Med       Date:  2014-06-06       Impact factor: 3.415

Review 2.  The path to personalised medicine in COPD.

Authors:  Alvar Agusti
Journal:  Thorax       Date:  2014-04-29       Impact factor: 9.139

3.  Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations.

Authors:  Alberto Papi; Cinzia Maria Bellettato; Fausto Braccioni; Micaela Romagnoli; Paolo Casolari; Gaetano Caramori; Leonardo M Fabbri; Sebastian L Johnston
Journal:  Am J Respir Crit Care Med       Date:  2006-02-16       Impact factor: 21.405

4.  Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial.

Authors:  Mona Bafadhel; Susan McKenna; Sarah Terry; Vijay Mistry; Mitesh Pancholi; Per Venge; David A Lomas; Michael R Barer; Sebastian L Johnston; Ian D Pavord; Christopher E Brightling
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

5.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.

Authors:  Mona Bafadhel; Susan McKenna; Sarah Terry; Vijay Mistry; Carlene Reid; Pranabashis Haldar; Margaret McCormick; Koirobi Haldar; Tatiana Kebadze; Annelyse Duvoix; Kerstin Lindblad; Hemu Patel; Paul Rugman; Paul Dodson; Martin Jenkins; Michael Saunders; Paul Newbold; Ruth H Green; Per Venge; David A Lomas; Michael R Barer; Sebastian L Johnston; Ian D Pavord; Christopher E Brightling
Journal:  Am J Respir Crit Care Med       Date:  2011-09-15       Impact factor: 21.405

6.  Eosinophilic inflammation in COPD: prevalence and clinical characteristics.

Authors:  Dave Singh; Umme Kolsum; Chris E Brightling; Nicholas Locantore; Alvar Agusti; Ruth Tal-Singer
Journal:  Eur Respir J       Date:  2014-10-16       Impact factor: 16.671

7.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321
  7 in total
  111 in total

1.  Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  Jeong H Yun; Andrew Lamb; Robert Chase; Dave Singh; Margaret M Parker; Aabida Saferali; Jørgen Vestbo; Ruth Tal-Singer; Peter J Castaldi; Edwin K Silverman; Craig P Hersh
Journal:  J Allergy Clin Immunol       Date:  2018-04-28       Impact factor: 10.793

Review 2.  Drugs for chronic obstructive pulmonary disease.

Authors:  Christine Jenkins
Journal:  Aust Prescr       Date:  2017-02-01

3.  Pharmacological treatment for COPD; GOLD 2017 changes direction.

Authors:  Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2017-03-09       Impact factor: 4.335

4.  Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention.

Authors:  Pradeep Karur; Dave Singh
Journal:  Ann Transl Med       Date:  2016-12

Review 5.  An update on the use of inhaled therapy in COPD.

Authors:  Oliver Price; Chandra Sarkar; Shruthi Konda
Journal:  Clin Med (Lond)       Date:  2018-10       Impact factor: 2.659

6.  Serum eosinophils as a COPD biomarker: ready for prime time?

Authors:  Anand S Iyer; Mark T Dransfield
Journal:  Lancet Respir Med       Date:  2016-04-07       Impact factor: 30.700

Review 7.  The Use of Inhaled Corticosteroids to Prevent Acute Exacerbations of COPD: A Pro/Con Debate.

Authors:  Richard E K Russell; Ian Pavord
Journal:  Turk Thorac J       Date:  2019-04-25

Review 8.  Management of the Asthma-COPD Overlap Syndrome (ACOS): a Review of the Evidence.

Authors:  Kristin L Hines; R Stokes Peebles
Journal:  Curr Allergy Asthma Rep       Date:  2017-03       Impact factor: 4.806

Review 9.  Asthma-chronic obstructive pulmonary disease overlap syndrome.

Authors:  Matthew F Mart; Ray Stokes Peebles
Journal:  Curr Opin Immunol       Date:  2020-11-22       Impact factor: 7.486

Review 10.  Targeting Chronic Obstructive Pulmonary Disease Phenotypes, Endotypes, and Biomarkers.

Authors:  Suresh Garudadri; Prescott G Woodruff
Journal:  Ann Am Thorac Soc       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.